<DOC>
	<DOCNO>NCT01498627</DOCNO>
	<brief_summary>This study aim ass whether use CervarixÂ® associate modify risk central demyelination , type 1 diabetes ( DT1 ) , Cutaneous Lupus , inflammatory arthritis , idiopathic thrombocytopenic purpura ( ITP ) , Lupus erythematosus , myositis dermatomyositis , Guillain-Barre syndrome and/or Autoimmune thyroiditis Graves disease use PGRx information system .</brief_summary>
	<brief_title>Cervarix Long-term Safety Surveillance</brief_title>
	<detailed_description>PGRx information system intend bridge resource gap assess effect drug risk adverse event infrequent and/or long delay onset . It use characteristic ad hoc case-control case-referent design , transpose prospective , on-going , population-based recruitment plan . This particular design call systematic case-referent design contrast ad hoc case-control case-referent methodology . The PGRx information system base routine target recruitment case series pathology , compare population-based referent study exposure wide variety drug . Drug exposure ascertainment obtain two different source PGRx . system : A ) A structured patient interview ( telephone-administered questionnaire ) B ) The medical data form computerize medical prescription ( interview guide )</detailed_description>
	<criteria>Male female Age 14 79 yearsold ( include ) Patient reside France Patient accept participate study Patient read respond telephone interview Prior report history disease Patient Patient 's parent read interview guide answer telephone interview questionnaire French Refusal participate</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Autoimmune disease ( AIDs )</keyword>
	<keyword>Cervarix</keyword>
	<keyword>PGRx information system</keyword>
</DOC>